PL1696940T3 - Uniwersalne osocze krwi, wytworzone częściowo z osocza pochodzącego od ludzi nie należących do rasy białej, pozbawione aktywnych wirusów - Google Patents

Uniwersalne osocze krwi, wytworzone częściowo z osocza pochodzącego od ludzi nie należących do rasy białej, pozbawione aktywnych wirusów

Info

Publication number
PL1696940T3
PL1696940T3 PL04804944T PL04804944T PL1696940T3 PL 1696940 T3 PL1696940 T3 PL 1696940T3 PL 04804944 T PL04804944 T PL 04804944T PL 04804944 T PL04804944 T PL 04804944T PL 1696940 T3 PL1696940 T3 PL 1696940T3
Authority
PL
Poland
Prior art keywords
blood
plasma
caucasian
portions
blood plasma
Prior art date
Application number
PL04804944T
Other languages
English (en)
Inventor
Andrea Heger
Jürgen Römisch
Tor-Einar Svae
Wolfgang Marguerre
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of PL1696940T3 publication Critical patent/PL1696940T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G23/00—Compounds of titanium
    • C01G23/04—Oxides; Hydroxides
    • C01G23/047—Titanium dioxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25—Silicon; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/29—Titanium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Geology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Environmental & Geological Engineering (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • External Artificial Organs (AREA)
PL04804944T 2003-12-19 2004-12-20 Uniwersalne osocze krwi, wytworzone częściowo z osocza pochodzącego od ludzi nie należących do rasy białej, pozbawione aktywnych wirusów PL1696940T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03029359 2003-12-19
EP04804944A EP1696940B1 (en) 2003-12-19 2004-12-20 A universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma
PCT/EP2004/053608 WO2005058334A1 (en) 2003-12-19 2004-12-20 A universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma

Publications (1)

Publication Number Publication Date
PL1696940T3 true PL1696940T3 (pl) 2007-08-31

Family

ID=34684548

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04804944T PL1696940T3 (pl) 2003-12-19 2004-12-20 Uniwersalne osocze krwi, wytworzone częściowo z osocza pochodzącego od ludzi nie należących do rasy białej, pozbawione aktywnych wirusów

Country Status (23)

Country Link
US (2) US20070071829A1 (pl)
EP (1) EP1696940B1 (pl)
JP (1) JP2007514716A (pl)
KR (1) KR101077976B1 (pl)
CN (1) CN1893960B (pl)
AT (1) ATE357242T1 (pl)
AU (1) AU2004298790B2 (pl)
BR (1) BRPI0417680A (pl)
CA (1) CA2550060A1 (pl)
CY (1) CY1106661T1 (pl)
DE (1) DE602004005501T2 (pl)
DK (1) DK1696940T3 (pl)
ES (1) ES2281848T3 (pl)
IL (1) IL175558A0 (pl)
NO (1) NO20062360L (pl)
PL (1) PL1696940T3 (pl)
PT (1) PT1696940E (pl)
RS (1) RS50508B (pl)
RU (1) RU2362571C2 (pl)
SI (1) SI1696940T1 (pl)
UA (1) UA83528C2 (pl)
WO (1) WO2005058334A1 (pl)
ZA (1) ZA200604941B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
FR2963737B1 (fr) * 2010-08-16 2013-04-05 Etat Francais Ministere De La Defense Service De Sante Des Armees Procede de lyophilisation de plasma sanguin
EP3093035A1 (en) 2015-05-13 2016-11-16 Sanofi-Aventis Deutschland GmbH Injection device for delivery of a liquid medicament
CN107496453A (zh) * 2017-08-13 2017-12-22 发贵科技（贵州）有限公司 一种有病毒灭活功能的血浆抗凝剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664913A (en) * 1982-05-24 1987-05-12 Xoma Corporation Method for treating plasma for transfusion
US4764369A (en) * 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
US5217627A (en) * 1990-11-06 1993-06-08 Pall Corporation System and method for processing biological fluid
AU667530B2 (en) * 1992-05-28 1996-03-28 New York Blood Center, Inc., The Removal of antibodies from blood-derived compositions while retaining coagulation factors
EP0896824A1 (en) * 1997-08-05 1999-02-17 Octapharma Ag A universally applicable blood plasma
CN1207004C (zh) * 2001-04-18 2005-06-22 马建川 通用型冻干血浆及其制备方法
US20030133829A1 (en) * 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material

Also Published As

Publication number Publication date
EP1696940B1 (en) 2007-03-21
CA2550060A1 (en) 2005-06-30
EP1696940A1 (en) 2006-09-06
BRPI0417680A (pt) 2007-03-20
DE602004005501T2 (de) 2007-11-29
RU2362571C2 (ru) 2009-07-27
US20110104298A1 (en) 2011-05-05
NO20062360L (no) 2006-05-23
KR20060126662A (ko) 2006-12-08
KR101077976B1 (ko) 2011-10-28
PT1696940E (pt) 2007-05-31
US20070071829A1 (en) 2007-03-29
CN1893960B (zh) 2012-10-31
AU2004298790B2 (en) 2010-04-08
DE602004005501D1 (de) 2007-05-03
ATE357242T1 (de) 2007-04-15
WO2005058334A1 (en) 2005-06-30
IL175558A0 (en) 2006-09-05
RS50508B (sr) 2010-03-02
SI1696940T1 (sl) 2007-08-31
AU2004298790A1 (en) 2005-06-30
UA83528C2 (uk) 2008-07-25
DK1696940T3 (da) 2007-07-30
CN1893960A (zh) 2007-01-10
JP2007514716A (ja) 2007-06-07
CY1106661T1 (el) 2012-05-23
ZA200604941B (en) 2007-11-28
RU2006126055A (ru) 2008-01-27
ES2281848T3 (es) 2007-10-01

Similar Documents

Publication Publication Date Title
LTPA2018502I1 (lt) Per burną vartojamos kladribino kompozicijos
BRPI0718688A8 (pt) Composições de baixa irritação e métodos para preparar as mesmas
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
RS20060320A (en) Substituted indazole-o-glucosides
DK1753440T3 (da) Oral administrationsform indeholdende probiotiske bakterier
BRPI0412254A (pt) produtos aril-heteroaromáticos, composições que os contêm e utilização
SG130189A1 (en) Substituted indole-o-glucosides
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
UA87991C2 (en) Substituted indole-o-glucosides
UA95715C2 (ru) Фосфадиазиновые производные, фармацевтическая композиция и их применение
IL178727A0 (en) Tetrahydropyridothiophene derivatives and pharmaceutical compositions containing the same
PL374080A1 (pl) Sposób wytwarzania fibrynogenu
IL175558A0 (en) A universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma
ATE334670T1 (de) Verwendung von mek-inhibitoren zur herstellung eines arzneimittels gegen negativstrang-rna-viren infektionen
BRPI0407176B8 (pt) composições compreendendo uma ou mais cepas de bifidobacterium e seus usos
BR9609416A (pt) Agentes antivìrus.
NO20032494L (no) Farmasoytisk blanding
DE602004008051D1 (de) Aus einer bifidobakterien-kultur gewonnener immunomodulator und diesen enthaltende zusammensetzungen
AU2002327970A1 (en) Inhibitors of costimulation by 0x40 and their use against infectious diseases
DE50207641D1 (de) Inaktivierung von genen des mep-wegs
RS20060323A (en) Substituted indole-o-glucosides
UA89625C2 (ru) Фосфонаты, монофосфонамидаты, бисфосфонамидаты для лечения вирусных заболеваний